Home > Boards > US OTC > Miscellaneous >

Quanta, Inc. (QNTA)

Add QNTA Price Alert      Hide Sticky   Hide Intro
Moderator: ProfitScout, PennyWorld, powerbattles, jedijazz, Skiluc, shoondale
Search This Board: 
Last Post: 5/21/2022 10:47:02 AM - Followers: 141 - Board type: Free - Posts Today: 1



Welcome to Quanta Inc. A Holdings Company


Here is the Medolife website when still private: https://medolife.com/
On May 10, 2021, the Company executed a Control Block Transfer Agreement with Phil Sands and Arthur Mikaelian, pursuant to which, effective Mr. Sands agreed to transfer 2,500,000 shares of the Company’s Series A Super Voting Preferred Stock to Dr. Mikaelian, representing a transfer of majority voting control over the Company because the holder of such 2,500,000 shares of our Series A Super Voting Preferred Stock automatically carries a vote equal to 51% on all matters submitted to a vote of the holders of our Common Stock and Preferred Stock. Mr. Sands agreed to transfer the Control Block to Arthur Mikaelian in exchange for 3,000,000 shares of the Company’s Common Stock, and for the payment of $22,500 in accrued salary, as well as the payment of health insurance benefits through January of 2022.
On December 21, 2020, Quanta, Inc. (the “Company”) entered into a Securities Exchange Agreement with Medolife Rx, Inc., a Wyoming corporation, (“Medolife Rx”) pursuant to which, the Company agreed to acquire 51% of Medolife Rx in exchange for 9,000 shares of newly created Series B Convertible Preferred Stock, which, once issued to Medolife Rx designees upon closing, shall be convertible into fifty-four percent (54%) of the issued and outstanding shares of the Company’s common stock on a fully converted basis.
So its actually: WELCOME TO MEDOLIFE! 
Medolife Rx was created through the merger of Medolife, a private company founded by Dr. Arthur Mikaelian who pioneered the unlaying polarization technology that makes the Company’s portfolio of pharmaceutical and nutraceutical products so effective, and Quanta, Inc., a direct-to-consumer wellness product portfolio company. 

Quanta Organics are being Sold on Amazon

Recent News:

Medolife Rx Announces Historic Product Registration in Dominican Republic Enabling Escozine to Be Sold Throughout Latin America as Natural Alternative Cancer Medicine 

Medolife Rx Breaks Ground on Lab Facility and Increases Scorpion Count at First-of-Its-Kind Reservation in the Dominican Republic

Medolife Rx (Quanta, Inc.) Reports Over $1 Million in Revenue in 2020 Year-End Filing, Comments on Operations

Quanta Inc., Groundbreaking Results In Escozine® Testing  

Medolife Rx Submits Final Data Set to FDA for IND Filing on Lead Drug Candidate 
April 13, 2021 08:30 ET


Medolife Rx And CURE Pharmaceutical Holding Corp. Collaborate For A Significant Increase Of Revenue

Following was pulled from SEC 10K April 15, 2021

Quanta for 2021 will be undergoing a name change to be announced shortly as well as Quanta is in the process of expanding its product line from 4 SKUs to 38 by summer. We will also be introducing all new branding with new color schemes, new packaging, and exciting celebrity endorsements for the pain relief products and a newly introduced beauty product line. Quanta will also be working on a men’s cosmetic line in conjunction with one of the celebrity endorsements planned for late 2021. The company has hired an advertising agency to help with the rollout of the new branding expected second quarter 2021. This will work in conjunction with a major push the company is on the path of with some major big box retail chains. 

Quanta Basics 

Quanta is a cutting-edge technology platform whose patented, proprietary technology harnesses advances in quantum biology to increase the potency of active ingredients. Currently, Quanta supports product formulations in pain management, anti-inflammation, skincare, agriculture, nutritional supplements, and plant-based consumables. Ultimately, Quanta’s mission is to deliver better, more effective ingredients to elevate product efficacy, reduce waste and facilitate healthier, more sustainable consumption. 

The established resonance theory behind Quanta’s polarization process has many potential applications. From potentiating bio-ingredients to produce more-effective carbon-trapping plants to transformative anti-aging solutions Quanta’s technology has the opportunity to upend how commercial products are made and the benefits from them. Already we see multi-trillion-dollar global industries benefiting from Quanta’s technology.

Our proof of concept, Quanta’s market-leading CBD pain-relief rub (“Muscle Rub”), is only the first in a series of paradigm shift products to emerge from our labs. At the heart of its well-documented effectiveness is our proprietary “polarization” process, which uses electromagnetic force to markedly enhance bioactivity at the molecular level—a polarized active ingredient is more soluble and creates stronger bonds with the body’s receptors. This allows us to enhance ingredients so they work faster and more powerfully without the use of chemical by-products or cellular penetration. Quanta believes this natural solution has nearly limitless applications in the world of plant-based consumer products. 

Quanta is involved in ambitious projects that we believe will reshape the next wave of climate science, sustainability, nutrition, and more. Having harnessed the technology of the future, Quanta is dedicated to bringing tomorrow’s health and wellness solutions to the billions in need today. 

Discovery Synopsys 

Using our product development process and business-to-business and direct-to-consumer sales approaches as a benchmark for future business, we developed the Quanta business model. Our technology’s unique ability to strengthen ingredients renders them more potent without added chemicals or penetrating cells means Quanta is in a first-of-its-kind position in the market. As the world’s first company focused on Quantum Biology we sit in a strong, but unique position in the market. 

Our ability to increase ingredient efficacy by up to 500% means we are in a rare position to truly disrupt many areas of material science. 

Quanta’s technology renders products superior to any on the market today. A 30% re-purchase rate (on one SKU alone) illustrates consumer appetite for the product. 

Upcoming products and ventures will be designed to achieve or surpass this level of consumer benefit and uptake.


Management Team

Arthur Mikaelian, Ph.D.

Chairman & CEO

One of Dr. Arthur Mikaelian’s greatest scientific contributions and groundbreaking inventions is Quantum Physics and Quantum Biology-based polarization technology, which targets molecular structure of the main ingredients in synthetic medications or natural compounds, leading to the increased potency of liquid and solid compounds, which substantially increases their therapeutic effectiveness. Dr. Mikaelian’s polarization technology has been awarded U.S. Patent 8,097,284B2 as it pertains to the Polarized Scorpion Venom solution. For the past 20 years, Dr. Mikaelian has been independently actively studying stress hormones (cortisol, epinephrine), and the master gene’s (ATF3) indirect influence on cancer cell activity and tumor progression. His initial findings quickly led him to the innovative creation of a new generation of pharmaceutical and nutraceuticals drugs, as well as expanding his interests in cancer and oncology.

Dr. Mikaelian’s education began in 1984 at the 2nd Medical Institute of Moscow and continued at the Vernadsky University of Biosphere Knowledge in Moscow, where he earned his doctorate in Biological/NeuroPsychology; he then went on to complete his postdoctoral work at Vernadsky. Dr. Mikaelian has broad experience with Quantum Physic and Quantum Biology. He also earned an MBA from the University of Bologna in Italy.

Khalid Matalka, Ph.D., SI(ASCP)

Chief Scientific Officer

Professor Khalid Matalka received his BSc and MSc in Medical Technology in 1986 and 1988 from Yarmouk University, Jordan, and the University of Wisconsin-Milwaukee, USA. Then he received his Ph.D. in Pathology (Immunology and Cancer therapy) from Ohio State University, USA, in 1992. After finishing his Ph.D., Dr. Matalka joined Harvard Medical School as a Postdoctoral fellow till 1994. He is an American Board Certified as a Specialist in Immunology (SI-ASCP) and a member at the American Society for Cancer Research since 1994.

Dr. Matalka enrolled in academia as an assistant professor in 1995, then promoted to associate and then a professor in 2004. Prof. Matalka held a dean position at two different academic institutions. Besides, Prof. Matalka was a consultant for twenty years to a JPM pharmaceutical company and a hospital diagnostic laboratory. During those 22 years, Prof. Matalka was heavily involved in research mainly on immunomodulation, cancer research, and development of immunological assays. In 2016, he joined a pharmaceutical startup company named OncoTherapeutica, MA as a Chief Biologist. While there, Prof. Matalka was developing new potential drugs for the treatment of prostate cancer and melanoma. In March 2020, Prof. Matalka joined Medolife Corporation as Chief Scientific Officer (CSO) and, in February 2021, became the CSO of the newly established Medolife Rx.

Prof. Matalka has 65 publications in peer-reviewed international journals, and he is an Associate Editor of two and a member of the editorial board of several international journals. Prof. Matalka is known as an international reviewer in the fields of Cancer therapy, Immunomodulation, and Ethnopharmacology.

Grant Mikaelian

Executive Vice President

In 2013, Mr. Grant Mikaelian began working for an advanced biopharmaceutical company called Medolife. During his employment, he amassed a wide range of skills through managing various departments of the company. As a Marketing Sales Department Manager, he led many successful projects to improve customer experience through website development and design, enhanced customer support, streamlined ordering systems, configuration of B2C/B2B logistics, company rebranding, and preparation of marketing literature and presentations. He was later promoted to Operations Manager, overseeing and optimizing company departments on a larger scale. He was involved in production planning, project management of short and long-term goals, hiring prospective employees and contractors, corporate IT improvements, equipment procurement, international product registrations, due diligence preparation, and financial audits. He came to inspire confidence and began working closely with Dr. Arthur Mikaelian, CEO of Medolife. Soon after, Mr. Mikaelian was further promoted to Chief Business Development Officer. As the CBDO, he worked with existing and potential shareholders, was involved in domestic and international investment opportunities, managed multiple departments, increased company and product awareness, expanded product distribution channels, drafted Press Releases and articles, edited and proofread company literature, and more. Mr. Mikaelian is an organized leader with broad experiences in management and promotion of corporate growth.

Clemente Pascarella

Audit Committee


Christopher Rullan

Attorney for Mexico Division


Eduard Sahakyan

Head of R&D

Dr. Sahakyan started his career at Glendale Community College (GGC) as a lab technician for the biology department. He then pursued a biotechnology major at Pasadena City College (PCC). During his studies he interned at the Pasadena Bio Collaborative (PBC) Incubator as part of the LA Bioscience Hub research outreach program. Dr. Sahakyan worked with multiple companies including UCLA, Amgen and others during his summer internship. Upon completion, he was offered a permanent position at BCN (UCLA research collaborative) where he completed multiple projects, some of them are pending publication. In 2019, Dr. Sahakyan was offered a position in Medolife as a research associate. Within a year he was promoted to head scientist. Throughout this time, Dr. Sahakyan has worked on a number of company projects, which he presented at different local and national conferences. One of his bigger projects is the differentiation of embryonic stem cells into red blood cells. He continuously brings new ideas and initiatives to the company.

Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
QNTA News: Notification That Quarterly Report Will Be Submitted Late (nt 10-q) 05/16/2022 02:01:22 AM
QNTA News: Form 8-K - Current report 04/28/2022 10:53:00 AM
QNTA News: Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 04/15/2022 02:29:00 PM
QNTA News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 03/28/2022 01:15:42 PM
QNTA News: Amended Quarterly Report (10-q/a) 11/23/2021 03:22:36 AM
#12323  Sticky Note QNTA_a_CON: BULLSHIT "CALL" REGURG_PUMP_ABOUT_NOTHING_WTF ??? Dragon Lady 05/04/22 01:20:08 PM
#12255  Sticky Note LMAO TOTAL BULLSHIT, I have some clarity now Dragon Lady 04/30/22 09:36:32 AM
#11903  Sticky Note News: Medolife Rx Announces Changes to Management and jedijazz 02/07/22 09:10:42 AM
#11796  Sticky Note News: Medolife Rx Submits Final Clinical Trial Data jedijazz 01/19/22 08:05:52 AM
#12461   Your welcome… here’s more key topics that were JediMozart 05/21/22 10:47:02 AM
#12460   Thanks you freedom 32 05/20/22 10:53:22 PM
#12459   That's great to see! Hoping the Mikaelian baby shoondale 05/20/22 03:00:23 PM
#12458   Your dedication to this stock is amazing... BlazingStocks 05/20/22 02:47:45 PM
#12457   Thanks! .. and your welcome, glad you JediMozart 05/20/22 02:37:56 PM
#12456   I agree, definitely an asset here. BlazingStocks 05/20/22 01:44:35 PM
#12455   Sounds great brother. Have a great weekend BlazingStocks 05/20/22 01:43:45 PM
#12454   It's really appreciated and it's also helpful for BlazingStocks 05/20/22 01:42:26 PM
#12452   $QNTA +14.29% closing the week strong! budfoxfun 05/20/22 01:35:18 PM
#12449   56:25 Dr Mikaelian expresses this is his life’s JediMozart 05/20/22 09:46:53 AM
#12448   ** Licensing discussed - Listen at the 50:00 JediMozart 05/20/22 08:46:26 AM
#12447   Due for a breakout soon! budfoxfun 05/20/22 08:24:53 AM
#12446   Looking forward to the Mikaelian baby closing deals shoondale 05/20/22 07:38:43 AM
#12445   Thanks a million Jedi for deep diving into PennyWorld 05/19/22 04:59:54 PM
#12444   Your most welcome. Check out 31:38 where they JediMozart 05/19/22 04:51:23 PM
#12443   Your welcome I’m trying to take some notes JediMozart 05/19/22 04:18:03 PM
#12442   Thank you for your insight... $QNTA BlazingStocks 05/19/22 03:26:35 PM
#12441   You've really been a huge help with regards BlazingStocks 05/19/22 12:32:43 PM
#12440   You’ll find dialogue in regards to your query JediMozart 05/19/22 08:25:55 AM
#12439   Thank you. I will check it out when shoondale 05/19/22 08:21:29 AM
#12438   Looks like they were taken down, on the ThoroughBread 05/19/22 08:17:00 AM
#12437   ThoroughBred, check under shoondale 05/19/22 08:03:54 AM
#12436   Maybe someone can discover how the Mikaelian baby shoondale 05/19/22 07:53:55 AM
#12435   Nobody asked such question for the CC, that's Fdc4 05/19/22 03:19:53 AM
#12434   recent CC minute mark discussing “avoiding future shareholder JediMozart 05/18/22 09:12:42 PM
#12433   Schoondale …. Asked “Which begs the question is JediMozart 05/18/22 05:00:54 PM
#12432   Excellent advice...The $QNTA CC answers many shareholder questions. BlazingStocks 05/18/22 02:59:01 PM
#12431   Stock investors should listen to the CC before PennyWorld 05/18/22 11:57:25 AM
#12430   JediMozart, you rock for breaking down the important BlazingStocks 05/18/22 11:41:12 AM
#12429   Thank you for sharing that information with the BlazingStocks 05/18/22 11:39:45 AM
#12428   At time stamp 8:56 during the cc (link JediMozart 05/18/22 10:11:52 AM
#12425   Which begs the question is family running FARMTEVSIK? shoondale 05/18/22 08:44:52 AM
#12424   There is a world of difference between common shoondale 05/18/22 08:30:09 AM
#12423   Do not sleep on this! Major mover! captharmony 05/17/22 09:23:20 PM
#12422   Your most welcome I like this quote from JediMozart 05/17/22 04:21:55 PM
#12421  Restored LMAO TOTAL BULLSHIT, Flight info was NOT for Ceo Dragon Lady 05/17/22 04:21:01 PM
#12420   Jedi, Thank you for following up and clarifying PennyWorld 05/17/22 04:15:04 PM
#12419  Restored QNTA_a_CON: NEW_ALL_TIMES_LOWS_DAILY !! TAGGED_.0029_TODAY - TRIPS_SOON !! Dragon Lady 05/17/22 04:14:20 PM
#12418   Flight info was NOT for Ceo I simply JediMozart 05/17/22 04:10:24 PM
#12417   Listen at Minute mark 19:00 “able to share publicly JediMozart 05/17/22 02:06:05 PM
#12416   On watch for news! budfoxfun 05/17/22 01:39:50 PM
#12415   no filings for 16 Months and still pink Current??? ThoroughBread 05/17/22 01:03:00 PM
#12414   Excellent post... $QNTA is being as transparent as possible. BlazingStocks 05/17/22 01:02:35 PM
#12413   Does any one know factually what the trip JediMozart 05/17/22 11:00:46 AM
#12412   It is absolutely insane not to be concerned shoondale 05/17/22 10:01:18 AM
#12410   “Two new Omicron variants are spreading. Will they JediMozart 05/16/22 10:12:09 PM
#12409   It never ceases to amaze me how some PennyWorld 05/16/22 12:13:53 PM
#12408   It would be great to see a transcript BlazingStocks 05/16/22 12:12:54 PM
#12406   Yawn … a ceo is traveling .. people JediMozart 05/16/22 11:34:05 AM
#12405   QNTA_a_CON: NT_10-Q aka_LATE_FILER_AGAIN_AS_I_SAID_THEY_WOULD !! Dragon Lady 05/16/22 09:32:27 AM
Consent Preferences